Opus Genetics, Inc. has disclosed a significant stock transaction involving its Chief Operating Officer, Joseph K. Schachle. The filing reveals that Schachle sold 4,767 shares of the company’s common stock on October 23, 2026. This transaction was executed to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units.

This event is noteworthy as it showcases how companies in the pharmaceutical preparations sector manage stock and employee compensation. The automatic sale of shares indicates a structured approach to handling the financial implications of equity compensation, which is common in the industry.

Background

Opus Genetics, Inc. operates within the pharmaceutical preparations industry, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol IRD. It is categorized as a smaller reporting company and is based in Durham, North Carolina. The firm has undergone several name changes in the past, with its most recent being in November 2020 from Ocuphire Pharma, Inc.

What the Filing Says

The SEC filing, accession number 0001140361-26-040908, details that Schachle's transaction involved the sale of 4,767 shares at a price of $3.565 per share. Following this transaction, he retains ownership of 286,673 shares. A footnote in the filing clarifies that the shares were sold automatically to meet tax obligations and does not reflect a discretionary trade.

Impact

This transaction may affect Opus Genetics' stock performance and investor perception, as it highlights the company's practices regarding equity compensation. Employees and stakeholders in the pharmaceutical preparations industry may also take note of how such transactions are handled, potentially influencing their own compensation strategies.

What's Next

The filing does not say what happens next.